| P/E (FY) | 24.4 | Sales (TTM) | $923.7M |
| Earnings (TTM) | $92.1M | ROE | 16.59% |
| Net Margin | 8.87% | ROIC | 15.92% |
| Debt / Equity | 0.57 | TD / EBITDA | 1.53 |
| EPS Growth 3Y | — | Sales Growth 3Y | 40.81% |
ANI Pharmaceuticals, Inc. is a biopharmaceutical company that develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. Its products include injectables, softgel capsules, Cortrophin gel, ILUVIEN, and YUTIQ, and it also manufactures oral solid dose products, semi-solids, liquids, topicals, and controlled substances. The company serves wholesalers, specialty and retail pharmacies, distributors, group purchasing organizations, hospitals, and healthcare providers.
| Market Cap | $1.98B | Trading Days | 5291 |
| 52W High | 99.50 |
| 52W Low | 62.61 |
| % Off High | −18.55% |
| YTD | 2.66% | 1Y | 21.86% |
| 3Y | 54.77% | 5Y | 142.93% |
| 10Y | 35.95% | Since incept. (ann.) | −2.92% |
US 96% · Non Us 4%
| Ann. Volatility (1Y) | 36.11% | Ann. Volatility (3Y) | 36.59% |
| Sharpe (1Y) | 0.73 | Sharpe (3Y) | 0.60 |
| Max Drawdown (1Y) | −28.66% | Max Drawdown (3Y) | −28.66% |
| Beta (3Y, vs SPY) | −0.21 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| PGEN | PRECIGEN, INC. | $1.97B | — |
| URGN | UroGen Pharma Ltd. | $1.99B | — |
| RAPP | Rapport Therapeutics, Inc. | $2.01B | — |
| VRDN | Viridian Therapeutics, Inc.\DE | $2.01B | — |
| AUPH | Aurinia Pharmaceuticals Inc. | $1.92B | 7.2 |
| ZBIO | Zenas BioPharma, Inc. | $2.04B | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $2.05B | — |
| HRMY | Harmony Biosciences Holdings, Inc. | $2.07B | 13.2 |
| BHVN | Biohaven Ltd. | $2.07B | — |
| IMUX | IMMUNIC, INC. | $2.08B | — |
| SLS | SELLAS Life Sciences Group, Inc. | $1.88B |
| SION | Sionna Therapeutics, Inc. | $2.10B | — |